Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism

Abstract excerpt

The presence of valine (V) at position 158 of FcgammaRllla (CD16) is known to improve clinical response to rituximab in indolent non-Hodgkin lymphoma (NHL). Little is known about the basic mechanisms for this observation. We examined natural killer (NK) cells from healthy donors representing the FcgammaRIIIa-158 polymorphic subgroups (V/V, V/F, and F/F) for gene transcript and cell surface CD16 expression,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glycosylation and Glycoproteins Research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to T-cell and B-cell Immunology